Healthcare -
Biotechnology - NASDAQ - US
$ 87.18
-0.502 %
$ 4.39 B
Market Cap
-18.4
P/E
1. INTRINSIC VALUE
Balance Sheet
Soleno Therapeutics, Inc.
| Current Assets | 294 M |
| Cash & Short-Term Investments | 291 M |
| Receivables | 0 |
| Other Current Assets | 2.45 M |
| Non-Current Assets | 37.1 M |
| Long-Term Investments | 27.2 M |
| PP&E | 2.98 M |
| Other Non-Current Assets | 6.89 M |
| Current Liabilities | 18.7 M |
| Accounts Payable | 8.88 M |
| Short-Term Debt | 526 K |
| Other Current Liabilities | 9.34 M |
| Non-Current Liabilities | 67.1 M |
| Long-Term Debt | 52.3 M |
| Other Non-Current Liabilities | 14.8 M |
EFFICIENCY
Earnings Waterfall
Soleno Therapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 188 M |
| Operating Income | -184 M |
| Other Expenses | -8.58 M |
| Net Income | -176 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Soleno Therapeutics, Inc.
| Net Income | -176 M |
| Depreciation & Amortization | 1.99 M |
| Capital Expenditures | -218 K |
| Stock-Based Compensation | 100 M |
| Change in Working Capital | 6.02 M |
| Others | -863 K |
| Free Cash Flow | -69.3 M |
Wall Street Analysts Price Targets
Soleno Therapeutics, Inc.
Wall Street analysts predict an average 1-year price target for SLNO of $84.6 , with forecasts ranging from
a
low of
$59 to a high of $121 .
SLNO Lowest Price Target
Wall Street Target
59 USD
-32.32%
SLNO Average Price Target
Wall Street Target
84.6 USD
-2.93%
SLNO Highest Price Target
Wall Street Target
121 USD
38.79%
4. DIVIDEND
ANALYSIS
SLNO does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Soleno Therapeutics, Inc.
Sold
0-3 MONTHS
339 K USD 1
3-6 MONTHS
200 M USD 8
6-9 MONTHS
1.69 M USD 4
9-12 MONTHS
65.6 M USD 5
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock
REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it has priced its previously announced underwritten public offering of 2,352,941 shares of its common stock at a price to the public of $85.00 per share. All of the shares are being sold by Soleno. In addition, Soleno has granted the underwriters a 30-day option to purchase up to an additional 352,941 shares of its common stock at the public offering price. The gross proceeds from the offering are expected to be approximately $200 million before deducting underwriting discounts and commissions and other offering expenses, assuming no exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about July 11, 2025, subject to satisfaction of customary closing conditions.
globenewswire.com
- 1 week ago
Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock
REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell $200 million of shares of its common stock in an underwritten public offering. In addition, Soleno intends to grant the underwriters a 30-day option to purchase up to an additional $30 million of shares of common stock. The proposed public offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
globenewswire.com
- 1 week ago
Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025
REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today certain preliminary unaudited financial and operational results for the three months ended June 30, 2025:
globenewswire.com
- 1 week ago
Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference
Conference is the first-ever international meeting jointly hosted by the Prader-Willi Syndrome Association | USA, the Foundation for Prader-Willi Research, and the International Prader-Willi Syndrome Organisation Conference is the first-ever international meeting jointly hosted by the Prader-Willi Syndrome Association | USA, the Foundation for Prader-Willi Research, and the International Prader-Willi Syndrome Organisation
globenewswire.com
- 1 month ago
Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome
REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Soleno's Marketing Authorization Application (MAA) seeking regulatory approval of Diazoxide Choline Prolonged-Release Tablets (previously referred to as DCCR) for the treatment of adults and children four years and older with Prader-Willi syndrome (PWS) who have hyperphagia had been validated by the European Medicines Agency (EMA).
globenewswire.com
- 2 months ago
Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader-Willi Syndrome
REDWOOD CITY, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced data presented from its clinical development program of VYKAT™ XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, at the Pediatric Endocrine Society (PES) Annual Meeting 2025, which was held May 15-18 in National Harbor, Maryland, USA. The presentation showed that resumption of VYKAT XR treatment in participants with PWS following a 16-week randomized withdrawal was associated with significant improvements in both hyperphagia and behavioral symptoms.
globenewswire.com
- 2 months ago
Soleno Therapeutics, Inc. (SLNO) Q1 2025 Earnings Call Transcript
Soleno Therapeutics, Inc. (NASDAQ:SLNO ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Brian Ritchie - LifeSci Advisors Anish Bhatnagar - Chief Executive Officer Meredith Manning - Chief Commercial Officer Jim Mackaness - Chief Financial Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Debjit Chattopadhyay - Guggenheim Securities Kristen Kluska - Cantor Leland Gershell - Oppenheimer Brian Skorney - Baird James Condulis - Stifel Myriam Belghiti - LifeSci Capital Yale Jen - Laidlaw Operator Greetings, and welcome to the Soleno Therapeutics First Quarter 2025 Earnings Conference Call. At this time, note that all participants are in a listen-only mode.
seekingalpha.com
- 2 months ago
Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results
REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM XR and reported financial results for the first quarter ended March 31, 2025.
globenewswire.com
- 2 months ago
Soleno Therapeutics (SLNO) is on the Move, Here's Why the Trend Could be Sustainable
Soleno Therapeutics (SLNO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
zacks.com
- 2 months ago
Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET
REDWOOD CITY, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its first quarter 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, May 7, 2025. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update on business operations.
globenewswire.com
- 2 months ago
Soleno Therapeutics Announces VYKAT(TM) XR Launch
REDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the U.S. commercial availability of VYKAT™ XR (diazoxide choline) extended-release tablets, the company's treatment for hyperphagia in patients four years of age and older with Prader-Willi syndrome (PWS), which was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025.
globenewswire.com
- 3 months ago
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug
Soleno's shares soar in the premarket hours following the FDA approval of Vykat XR (diazoxide choline) for treating hyperphagia in PWS patients.
zacks.com
- 3 months ago
8. Profile
Summary
Soleno Therapeutics, Inc. SLNO
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 4.39 B
Dividend Yield
0.00%
Description
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Contact
203 Redwood Shores Parkway, Redwood City, CA, 94065
https://soleno.life
IPO
Date
Nov. 13, 2014
Employees
115
Officers
Dr. Anish Bhatnagar M.D.
Chairman, President, Chief Executive Officer & Chief Operating Officer
Dr. Neil M. Cowen M.B.A., Ph.D.
Senior Vice President of Drug Development
Dr. Michael Huang M.D.
Senior Vice President of Clinical Development
Ms. Patricia C. Hirano M.P.H.
Senior Vice President of Regulatory Affairs
Dr. Mitchell Nagao M.B.A., Pharm.D.
Senior Vice President of Medical Affairs
Ms. Kristen Yen M.S.
Senior Vice President of Global Clinical Operations and Patient Advocacy
Ms. Meredith Manning M.B.A.
Chief Commercial Officer
Ms. Lauren Budesheim
Vice President of People
Mr. James H. MacKaness
Chief Financial Officer & Compliance Officer
Mr. Jesse Schumaker
General Counsel